Service interruption on Monday 11 July from 12:30 to 13:00: all the sites of the CCSD (HAL, EpiSciences, SciencesConf, AureHAL) will be inaccessible (network hardware connection).
Skip to Main content Skip to Navigation
Journal articles

What do we learn from HER2-positive breast cancer genomic profiles?

Abstract : ABSTRACT: Patients with a tumor presenting amplification of the HER2 gene are currently proposed trastuzumab (herceptin) and this has greatly changed their outcome. However, a number of HER2-positive cancers show intrinsic or acquired resistance to trastuzumab and there are clear indications that they form a heterogeneous group of tumors. A paper in this issue of Breast Cancer Research addresses this heterogeneity at the genomic level.
Document type :
Journal articles
Complete list of metadata
Contributor : Yves Le Ster Connect in order to contact the contributor
Submitted on : Friday, June 11, 2010 - 3:47:52 PM
Last modification on : Tuesday, July 5, 2022 - 9:16:01 AM
Long-term archiving on: : Friday, September 17, 2010 - 1:26:40 PM


Files produced by the author(s)



Charles Theillet. What do we learn from HER2-positive breast cancer genomic profiles?. Breast Cancer Research, BioMed Central, 2010, 12 (3), pp.107. ⟨10.1186/bcr2571⟩. ⟨inserm-00491423⟩



Record views


Files downloads